U.S. Antibody Drug Conjugates Market Size & Outlook
U.S. antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
U.S. antibody drug conjugates market highlights
- The U.S. antibody drug conjugates market generated a revenue of USD 3,223.0 million in 2021 and is expected to reach USD 10,163.3 million by 2030.
- The U.S. market is expected to grow at a CAGR of 13.6% from 2022 to 2030.
- In terms of segment, breast cancer was the largest revenue generating application in 2021.
- Other Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 3,223.0 million |
| Market revenue in 2030 | USD 10,163.3 million |
| Growth rate | 13.6% (CAGR from 2021 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Other Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer, Urothelial Cancer & Bladder Cancer, Other Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, U.S. accounted for 55.5% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 401.8 million by 2030.
Breast cancer was the largest segment with a revenue share of 52.94% in 2021. Horizon Databook has segmented the U.S. antibody drug conjugates market based on blood cancer, breast cancer, urothelial cancer & bladder cancer, other cancer covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S.is a major market for ADCs, owing to factors such as high awareness by healthcare professionals about ADCs, presence of advanced ADCs, and high R&D investment by manufacturers. For instance, three new ADCs, Polivy, Padcev, and Enhertu, were approved in 2019 in the U.S.
In 2020, an accelerated FDA approval was granted to Blenrep (belantamab mafodotin-blmf), an ADC intended for treating adult patients with multiple myeloma who have previously received at least 4 prior therapies, including an anti-CD-38 monoclonal antibody, a proteasome inhibitor and immunomodulatory agent.
Furthermore, favorable reimbursement policies are expected to drive market growth in the country. For instance, Gene tech provides a co-pay program for Kadcyla to patients, alleviating their out-of-pocket expenses on the condition that the medication is being administered for an FDA-approved indication, while making the assistance ineligible for patients that are using state or federal programs to pay for their medications.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. antibody drug conjugates market size, by application, 2018-2030 (US$M)
U.S. Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
